I thought bisantrene concentration and FTO inhibition, just like with cardioprotection, is not linearly related and is dose-dependent. One big thing with bisantrene is synergy synergy synergy. It makes other drugs work better, at no added cost to the patient. So in Sheba 2, it is possible the response rates are not related to FTO etc but due to the other 2 combo drugs. We won't know until more data is released, but it's a win-win. Either it's FTO, or it's still bisantrene, but by amplifying the impact of the other drugs. Just my thoughts
- Forums
- ASX - By Stock
- RAC
- Ann: Impressive Bisantrene Phase 2 AML Clinical Results
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-107
-
- There are more pages in this discussion • 125 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.88 |
Change
0.115(6.52%) |
Mkt cap ! $322.7M |
Open | High | Low | Value | Volume |
$1.78 | $1.93 | $1.78 | $548.6K | 294.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 700 | $1.87 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.88 | 396 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 700 | 1.865 |
2 | 1804 | 1.860 |
2 | 8000 | 1.855 |
3 | 56350 | 1.850 |
1 | 346 | 1.845 |
Price($) | Vol. | No. |
---|---|---|
1.875 | 550 | 1 |
1.880 | 480 | 2 |
1.885 | 1300 | 1 |
1.890 | 5000 | 1 |
1.895 | 43 | 1 |
Last trade - 15.30pm 11/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |